Radiation Oncology (Sep 2021)

Palliative radiotherapy for painful lymph node metastases

  • Kohsei Yamaguchi,
  • Tetsuo Saito,
  • Ryo Toya,
  • Etsushi Tomitaka,
  • Tomohiko Matsuyama,
  • Yoshiyuki Fukugawa,
  • Takahiro Watakabe,
  • Hirohito Otsuka,
  • Natsuo Oya

DOI
https://doi.org/10.1186/s13014-021-01900-8
Journal volume & issue
Vol. 16, no. 1
pp. 1 – 7

Abstract

Read online

Abstract Background There is limited evidence concerning radiotherapy for painful lymph node metastases (PLM). We evaluated the effectiveness of radiotherapy for PLM using the International Consensus Endpoint in a subgroup analysis of a prospective observational study. Methods In the primary study, 302 patients received radiotherapy for painful tumors. Among them, those treated with palliative radiotherapy for PLM were analyzed in the present study. We used the Brief Pain Inventory short form to evaluate the intensity of pain and the pain interference in patient's life. We collected the Brief Pain Inventory and analgesic data at baseline and at 1, 2, and 3 months after the start of radiotherapy. Pain response was assessed using the International Consensus Endpoint. Patients were diagnosed with a predominance of other pain (POP) if non-index pain of a malignant or unknown origin was present and had a greater 'worst pain' score than the index pain. Results Radiotherapy for PLM was performed on 25 patients. In total, 15 (60%) patients experienced a pain response. The pain response rates for evaluable patients were 66%, 67%, and 57% at 1-, 2-, and 3-month follow-ups, respectively. At baseline and at 1, 2, and 3 months, the median index pain scores were 7, 2, 0, and 0.5, respectively. At 1 month, all pain interference scores were significantly reduced from baseline. Four (16%) patients experienced POP within three months. Conclusion Radiotherapy for PLM improved pain intensity and pain interference. Palliative radiotherapy may be a viable treatment option for PLM.

Keywords